Cargando…

Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy

Off-target toxicity due to the expression of target antigens in normal tissue or TCR cross-reactivity represents a major risk when using T cell receptor (TCR)-engineered T cells for treatment of solid tumours. Due to the inherent cross-reactivity of TCRs it is difficult to accurately predict their t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mensali, Nadia, Myhre, Marit Renée, Dillard, Pierre, Pollmann, Sylvie, Gaudernack, Gustav, Kvalheim, Gunnar, Wälchli, Sébastien, Inderberg, Else Marit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6682583/ https://www.ncbi.nlm.nih.gov/pubmed/31214732 http://dx.doi.org/10.1007/s00262-019-02356-2

Ejemplares similares

Correction to: Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
por: Mensali, Nadia, et al.
Publicado: (2019)

NK cells specifically TCR-dressed to kill cancer cells
por: Mensali, Nadia, et al.
Publicado: (2019)

Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy
por: Dillard, Pierre, et al.
Publicado: (2021)

Antigen-delivery through invariant chain (CD74) boosts CD8 and CD4 T cell immunity
por: Mensali, Nadia, et al.
Publicado: (2019)

Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors
por: Dillard, Pierre, et al.
Publicado: (2021)

A TCR-based Chimeric Antigen Receptor
por: Walseng, Even, et al.
Publicado: (2017)

T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces in vivo tumor growth
por: Inderberg, Else M., et al.
Publicado: (2017)

Long-term surviving cancer patients as a source of therapeutic TCR
por: Inderberg, Else Marit, et al.
Publicado: (2020)

Emerging Biomarkers for Immunotherapy in Glioblastoma
por: Mensali, Nadia, et al.
Publicado: (2022)

Combinatorial CAR design improves target restriction
por: Köksal, Hakan, et al.
Publicado: (2020)

Sympathetic improvement of cancer vaccine efficacy
por: Inderberg, Else Marit, et al.
Publicado: (2020)

A phase I/II escalation trial design T-RAD: Treatment of metastatic lung cancer with mRNA-engineered T cells expressing a T cell receptor targeting human telomerase reverse transcriptase (hTERT)
por: Maggadóttir, Sólrún Melkorka, et al.
Publicado: (2022)

Colorectal cysts as a validating tool for CAR therapy
por: Dillard, Pierre, et al.
Publicado: (2020)

Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001
por: Inderberg-Suso, Else-Marit, et al.
Publicado: (2012)

Determination of CAR T cell metabolism in an optimized protocol
por: Joaquina, Sandy, et al.
Publicado: (2023)

hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes
por: Suso, Else M. Inderberg, et al.
Publicado: (2011)

ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma
por: Mensali, Nadia, et al.
Publicado: (2023)

Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials
por: Ellingsen, Espen Basmo, et al.
Publicado: (2022)

Artesunate shows potent anti-tumor activity in B-cell lymphoma
por: Våtsveen, Thea Kristin, et al.
Publicado: (2018)

Chimeric antigen receptor preparation from hybridoma to T-cell expression
por: Köksal, Hakan, et al.
Publicado: (2019)

P611: CD37 AS A MOLECULAR TARGET FOR CAR-T CELLS AGAINST CHRONIC LYMPHOCYTIC LEUKEMIA
por: Kusowska, Aleksandra, et al.
Publicado: (2023)

Posttransplantation Lymphoproliferative Disease Treated by Retransplantation
por: Weum Abrahamsen, Ingerid, et al.
Publicado: (2020)

Simultaneous defeat of MCF7 and MDA-MB-231 resistances by a hypericin PDT–tamoxifen hybrid therapy
por: Theodossiou, Theodossis A., et al.
Publicado: (2019)

Peptide vaccine targeting mutated GNAS: a potential novel treatment for pseudomyxoma peritonei
por: Flatmark, Kjersti, et al.
Publicado: (2021)

Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma
por: Vik-Mo, Einar Osland, et al.
Publicado: (2013)

TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals
por: Manfredi, Francesco, et al.
Publicado: (2020)

Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer
por: Brunsvig, Paal F., et al.
Publicado: (2020)

A full scale comparative study of methods for generation of functional Dendritic cells for use as cancer vaccines
por: Jarnjak-Jankovic, Silvija, et al.
Publicado: (2007)

Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain
por: Kuball, Jürgen, et al.
Publicado: (2009)

Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial
por: Aamdal, Elin, et al.
Publicado: (2021)

Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination
por: Ellingsen, Espen Basmo, et al.
Publicado: (2022)

Fine-Tuning of Optimal TCR Signaling in Tumor-Redirected CD8 T Cells by Distinct TCR Affinity-Mediated Mechanisms
por: Presotto, Danilo, et al.
Publicado: (2017)

In vitro and in vivo properties of CD133 expressing cells from human lung cancer cell lines
por: Wang, Ping, et al.
Publicado: (2013)

Identification and Characterization of Cells with Cancer Stem Cell Properties in Human Primary Lung Cancer Cell Lines
por: Wang, Ping, et al.
Publicado: (2013)

Efficient chimeric antigen receptor targeting of a central epitope of CD22
por: Casey, Nicholas Paul, et al.
Publicado: (2023)

Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor
por: Zhang, Ge, et al.
Publicado: (2014)

Expansion of donor-unrestricted MAIT cells with enhanced cytolytic function suitable for TCR redirection
por: Parrot, Tiphaine, et al.
Publicado: (2021)

Personalized Armored TCR-Redirected T Cell Therapy for Liver/Organ Transplant with Recurrent Cancer
por: Hafezi, Morteza, et al.
Publicado: (2021)

Redirecting the focus of cancer immunotherapy to premalignant conditions
por: Young, M. Rita I.
Publicado: (2017)

Covalent TCR-peptide-MHC interactions induce T cell activation and redirect T cell fate in the thymus
por: Szeto, Christopher, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4im77b05g16p8hakjvtlqcikug